0001104659-23-057487.txt : 20230509 0001104659-23-057487.hdr.sgml : 20230509 20230509075046 ACCESSION NUMBER: 0001104659-23-057487 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AdaptHealth Corp. CENTRAL INDEX KEY: 0001725255 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 823677704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38399 FILM NUMBER: 23900029 BUSINESS ADDRESS: STREET 1: 220 WEST GERMANTOWN PIKE STREET 2: SUITE 250 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: 610-630-6357 MAIL ADDRESS: STREET 1: 220 WEST GERMANTOWN PIKE STREET 2: SUITE 250 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 FORMER COMPANY: FORMER CONFORMED NAME: DFB Healthcare Acquisitions Corp. DATE OF NAME CHANGE: 20171213 8-K 1 tm2315007d1_8k.htm FORM 8-K
0001725255 false 0001725255 2023-05-08 2023-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2023

 

 

AdaptHealth Corp.

(Exact name of registrant as specified in its charter)

 

Delaware  001-38399  82-3677704
(State or other jurisdiction of
incorporation)		  (Commission File Number)  (IRS Employer Identification No.)

 

220 West Germantown Pike, Suite 250

Plymouth Meeting, PA

   19462
(Address of principal executive offices)   (Zip Code)
     
(610) 424-4515

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share AHCO The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 5.02(b) and (e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 8, 2023, AdaptHealth Corp. (the “Company”) and Stephen P. Griggs, Chief Executive Officer of the Company, mutually agreed that Mr. Griggs will resign as Chief Executive Officer of the Company, effective as of 11:59 p.m. E.D.T. on June 30, 2023 (or the date of his death or “disability” if earlier) (the effective date of his resignation being, the “Separation Date”). It is further agreed that Mr. Griggs will not stand for reelection as a member of the Company’s Board of Directors (the “Board”) at the Company’s annual meeting currently scheduled for June 21, 2023.

 

In connection with Mr. Griggs’ resignation, the Company entered into a transition letter agreement with Mr. Griggs, dated May 8, 2023 (the “Transition Agreement”), pursuant to which Mr. Griggs will continue to serve as the Chief Executive Officer of the Company until the Separation Date or until such earlier time that a new chief executive officer is appointed. If a new chief executive officer is appointed prior to the Separation Date, Mr. Griggs will serve as an advisor through the Separation Date and his primary responsibility will be to assist in the smooth transition of his duties, responsibilities and business relationships to the new chief executive officer.

 

Subject to Mr. Griggs’ continuous employment with the Company through, and provided that “cause” does not exist as of, the Separation Date, Mr. Griggs is eligible to receive the following separation benefits pursuant to the Transition Agreement: (i) the contractual severance benefits that Mr. Griggs would have been entitled to receive pursuant to his existing employment agreement (the “Employment Agreement”) in connection with a resignation by Mr. Griggs for “good reason,” (ii) a pro rata percentage of the portion of the annual bonus for the 2023 fiscal year that is based on individual performance, as assessed through the Separation Date, payable on or prior to August 15, 2023, (iii) a pro rata percentage of the portion of the annual bonus for the 2023 fiscal year that is based on the level of achievement of the Company’s adjusted EBITDA and free cash flow goals for the 2023 fiscal year, payable at the same time as annual bonuses are paid to senior executives of the Company, (iv) full vesting of any outstanding equity awards subject exclusively to time-based vesting criteria, and (v) continued eligibility to vest in any outstanding equity awards subject to performance-based vesting criteria without regard to any continued employment or service conditions. Mr. Griggs’ receipt of the foregoing separation benefits is further subject to his satisfaction of the terms and conditions of his receipt of the severance benefits under the Employment Agreement, including, without limitation, his timely execution and non-revocation of a release of claims and continued compliance with his restrictive covenants.

 

The foregoing description of the Transition Agreement is qualified in its entirety by reference to the complete text of the Transition Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

The Company’s Board is working with a leading executive search firm to identify a new chief executive officer and is considering several qualified candidates. Richard Barasch, Chairman of the Board, is expected to serve as interim chief executive officer if a successor to Mr. Griggs is not appointed by the time of his departure.

 

Item 7.01. Regulation FD Disclosure

 

On May 9, 2023, the Company issued a press release announcing the events described in Item 5.02 above. A copy of the press release is furnished as Exhibit 99.1.

 

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No. Description

 

10.1Transition Letter Agreement, between AdaptHealth Corp. and Stephen P. Griggs, dated May 8, 2023.

 

99.1Press Release dated May 9, 2023.
   
 104Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: May 9, 2023

 

  AdaptHealth Corp.
   
  By: /s/ Jason Clemens
    Name: Jason Clemens
    Title: Chief Financial Officer

 

-3-

 

 EX-10.1 2 tm2315007d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

ADAPTHEALTH CORP.

 

May 8, 2023

 

Stephen P. Griggs

via electronic delivery

 

Re: Transition Agreement

 

Dear Steve,

 

Reference is made to that certain Employment Agreement by and between you and AdaptHealth Corp. (the “Company”), dated as of February 1, 2021 (the “Employment Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.

 

This letter is intended to set forth our mutual agreement with respect to the termination of your employment with the Company. By signing below, you hereby resign from all positions that you hold with the Company Group (including as an executive officer and a director), effective as of the earlier of (i) 11:59pm E.D.T. on June 30, 2023, and (ii) the date on which your employment is terminated on account of your death or Disability in accordance with the terms of the Employment Agreement (the earlier of (i) and (ii) being the “Separation Date” and the period commencing on the date hereof and ending on the Separation Date being, the “Transition Period”). Further, it is agreed that you will not stand for reelection as a member of the Board at the annual meeting currently scheduled for June 21, 2023.

 

At all times during the Transition Period, you will continue to devote your full business time (unless otherwise requested by the Chairman of the Board), attention, skill and best efforts and will not engage in any other business or occupation (consistent with the terms of the Employment Agreement). You will to continue to serve as the Company’s Chief Executive Officer during the portion of the Transition Period prior to the date on which a new chief executive officer (your “Successor”) commences serving in such role (the “CEO Transition Date”). During the portion of the Transition Period, if any, following the CEO Transition Date, you will serve as an advisor to the Board and the Company’s senior management team and your primary responsibility will be to ensure a smooth transition of your duties and responsibilities to your Successor and to assist the Company Group and its counsel in connection with any investigation, administrative proceeding or litigation related to any matter in which you were involved or have knowledge. Further, at all times during the Transition Period, you will use your best efforts to maintain and solidify the Company Group’s relationships with its vendors and clients and to effectively transition such relationships to your Successor (once identified) or such other employees of the Company Group designated by the Chairman of the Board or your Successor. You agree that neither the appointment of your Successor nor your transition to an advisor or any changes to your duties, responsibilities or authority resulting therefrom will give rise to Good Reason for purposes of the Employment Agreement or otherwise.

 

 

 

 

During the Transition Period, you will continue to be paid your Base Salary (at a rate of $625,000 per annum) in accordance with the Employment Agreement, continue to vest in any outstanding equity awards in accordance with their respective terms and continue to participate in the Company Group benefit plan in which you participate as of the date hereof (subject to the terms of such plans). Further, subject to your continuous employment through, and provided that Cause does not exist as of, the Separation Date, the Company has agreed to treat your resignation as a resignation for Good Reason for purposes of the Employment Agreement and, in connection with such resignation, you will be entitled to the following payments and benefits (collectively, the “Separation Benefits”):

 

(i)the Severance Benefits;

 

(ii)a pro rata percentage of the portion of the Annual Bonus in respect of the 2023 fiscal year that is based on the Compensation Committee’s assessment of your individual performance, which shall be in an amount equal to the product of (x) $156,250 (which, for the avoidance of doubt, is 25% of your target Annual Bonus), (y) your individual performance percentage as determined by the Compensation Committee on or prior to the payment date, and (z) a fraction (the “Pro Rata Percentage”), the numerator of which is the number of days during the 2023 calendar year from January 1, 2023 through and including the Separation Date, and the denominator of which is 365, such amount to be payable on or prior to August 15, 2023;

 

(iii)a pro rata percentage of the portion of the Annual Bonus in respect of the 2023 fiscal year that is based on the level of achievement of the adjusted EBITDA and free cash flow goals previously established by the Compensation Committee for the Company’s 2023 fiscal year (the “2023 Goals”), which shall be in an amount equal to the product of (x) $468,750 (which, for the avoidance of doubt, is 75% of your target Annual Bonus), (y) the payout percentage determined by the Compensation Committee with respect to the achievement of the 2023 Goals (which percentage shall be the same payout percentage as is generally applied in the determination of 2023 annual bonuses for the Company’s other senior executives), and (z) the Pro Rata Percentage, such amount to be payable at such time annual bonuses are generally paid to other senior executives of the Company, but in no event later than March 15, 2024;

 

(iv)full vesting of any outstanding equity awards subject exclusively to time-based vesting criteria as of the Separation Date; and

 

(v)continued eligibility to vest in any outstanding equity awards subject to performance-based vesting criteria without regard to any continued employment or service conditions.

 

Your receipt of the Separation Benefits is subject to your satisfaction of the terms and conditions to your receipt of the Severance Benefits as set forth in the Employment Agreement (including, without limitation, your timely execution (and non-revocation) of a Release of Claims and continued compliance with the covenants set forth in the Restrictive Covenant Agreement). In the event that any portion of the Separation Benefits would be payable prior to the effective date of the Release of Claims, such amounts will not be paid until the first regularly scheduled payroll date of the Company following the effective date of the Release of Claims. For the avoidance of doubt, in the event that your employment is terminated by the Company with Cause or you resign without Good Reason, in either case, prior to the Separation Date, you shall not be eligible for the payments or benefits described above.

 

2 

 

 

The Company shall, promptly following your submission of an invoice from your attorney, reimburse you for your actual attorneys’ fees associated with the review and analysis of the Employment Agreement, your existing equity awards, the negotiation and drafting of this letter and related advise to you, up to a maximum of $25,000.

 

The Company agrees to instruct its officers and directors not to make any disparaging or defamatory comments regarding you from and after the date hereof, provided that you comply with your obligations pursuant to the Restrictive Covenant Agreement. However, nothing in this paragraph will apply to disclosures required by applicable law, regulation or order of a court or governmental agency. Further, nothing in this paragraph will prohibit any director or officer from speaking truthfully with law enforcement or the Company’s or his or her counsel.

 

The Company shall use commercially reasonable efforts to remove you from state and federal registrations in a timely manner following the Separation Date, and you agree to cooperate with the Company in connection with such efforts including, but not limited to, by supplying any information that may be required and executing all necessary documents in a timely manner.

 

All payments to you hereunder shall be subject to any and all applicable taxes, as required by applicable Federal, state, local and foreign law and regulations.

 

This letter constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions. This letter (and your right to any payments hereunder) is non-transferable and may not be assigned, pledged or encumbered in any way by you. By signing below, you acknowledge and agree that both the Employment Agreement and the Restrictive Covenant Agreement remain in full force and effect in accordance with their respective terms except as explicitly modified by this letter.

 

This letter may be executed in any number of counterparts, any of which may be executed and transmitted by DocuSign, facsimile or “.pdf”, and each of which shall be deemed to be an original, but all of which together shall be deemed to be one and the same instrument.

 

This letter shall be governed in all respects, including as to validity, interpretation and effect, by the internal laws of the State of New York, without giving effect to the choice of law principles thereof.

 

*            *            *

 

[The remainder of this page is intentionally left blank.]

 

3 

 

 

Please confirm that the foregoing accurately reflects our mutual agreement by signing below and returning a fully executed copy to me on or before May 8, 2023.

 

  Sincerely,
   
  ADAPTHEALTH CORP.
   
  By: /s/ Christopher Joyce
  Name: Christopher Joyce
  Title: General Counsel
   
Acknowledged and agreed as of this 8th day of May, 2023 by:  
   
/s/ Stephen P. Griggs  
Stephen P. Griggs  

 

 

[Signature page to S. Griggs Transition Agreement]

 

 EX-99.1 3 tm2315007d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

AdaptHealth Announces Stephen Griggs Will Step Down as CEO at the End of Second Quarter

 

Board Has Initiated a Search for a Successor

 

Plymouth Meeting, PA – May 9, 2023 – AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies and related services, announced today that Stephen Griggs will step down as Chief Executive Officer by mutual agreement with the Board of Directors, effective June 30, 2023.

 

The Board is working with a leading executive search firm to identify a new CEO and is considering several qualified candidates. Richard Barasch, Chairman of the Board, will serve as interim CEO if a successor to Mr. Griggs is not appointed by the time of his departure. Mr. Griggs will not seek re-election to the Board at the Company’s forthcoming annual meeting in June.

 

Mr. Griggs joined AdaptHealth in 2021 following its acquisition of AeroCare Holdings, Inc., which he founded in 2000 and led as President and CEO until the acquisition. Under his leadership, AdaptHealth added key vendors, launched cross-selling initiatives, integrated its cloud-based workstreams and pioneered e-prescribe, e-ordering and e-delivery services.

 

Mr. Barasch said, “On behalf of the Board, I thank Steve for the critical leadership role he has played at AdaptHealth to help build a market-leading provider of sleep, diabetes, respiratory and other health care solutions. As CEO, he has led the Company through the successful integration of AdaptHealth and AeroCare, overseen more than two dozen acquisitions and helped us navigate the challenges of the COVID-19 pandemic, the CPAP shortage resulting from the Philips recall and other market headwinds. Steve leaves AdaptHealth in sound financial condition and much improved operational shape, and we are committed to finding a highly qualified candidate to capitalize on the strategic opportunities that will power the next stage of the Company’s growth.”

 

Mr. Griggs said, “I am proud to have worked with the most talented individuals in the industry to deliver on our vision of transforming the health care experience for patients by helping to keep them healthy at home. Now is the right time for a new leader to build on our strong foundation of cost-effective, scalable technology and established, trusted patient relationships. I look forward to working with Richard, the Board and our leadership team to ensure an effective transition.”

 

AdaptHealth also reported its first quarter 2023 earnings today. The Company looks forward to hosting a teleconference at 8:30 a.m. ET to discuss its results and business activities, including the leadership transition, with analysts and investors.

 

 

 

About AdaptHealth Corp.

 

AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to challenges in their activities of daily living, and thrive. Product and service offerings include (i) sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) HME to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 3.9 million patients annually in all 50 states through its network of approximately 725 locations in 47 states.

 

Contacts

 

AdaptHealth Corp.

 

Jason Clemens, CFA

Chief Financial Officer

 

Jason.clemens@adapthealth.com

 

 

 EX-101.SCH 4 ahco-20230508.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ahco-20230508_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ahco-20230508_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 08, 2023
Entity File Number 001-38399
Entity Registrant Name AdaptHealth Corp.
Entity Central Index Key 0001725255
Entity Tax Identification Number 82-3677704
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 220 West Germantown Pike
Entity Address, Address Line Two Suite 250
Entity Address, City or Town Plymouth Meeting
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19462
City Area Code 610
Local Phone Number 424-4515
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol AHCO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2315007d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001725255 2023-05-08 2023-05-08 iso4217:USD shares iso4217:USD shares 0001725255 false 8-K 2023-05-08 AdaptHealth Corp. DE 001-38399 82-3677704 220 West Germantown Pike Suite 250 Plymouth Meeting PA 19462 610 424-4515 false false false false Common Stock, par value $0.0001 per share AHCO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adapthealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2315007d1_8k.htm ahco-20230508.xsd ahco-20230508_lab.xml ahco-20230508_pre.xml tm2315007d1_ex10-1.htm tm2315007d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2315007d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2315007d1_8k.htm" ] }, "labelLink": { "local": [ "ahco-20230508_lab.xml" ] }, "presentationLink": { "local": [ "ahco-20230508_pre.xml" ] }, "schema": { "local": [ "ahco-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ahco", "nsuri": "http://adapthealth.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315007d1_8k.htm", "contextRef": "From2023-05-08to2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://adapthealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315007d1_8k.htm", "contextRef": "From2023-05-08to2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adapthealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-057487-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-057487-xbrl.zip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end